The national procurement of proprietary Chinese medicines is approaching, and pharmaceutical machine companies usher in new opportunities

Recently, the State Council Information Office held a regular policy briefing to reveal that: the next step, the National Medical Insurance Bureau will normalize and institutionalize the centralized procurement of drugs and high-value medical consumables.
The three major sectors of medicine are carried out, and high-value medical consumables focus on orthopedic consumables, drug balloons, dental implants and other varieties
.
The national procurement of proprietary Chinese medicines is approaching, and pharmaceutical machine companies will usher in new opportunities (Photo source: Pharmaceutical Network) It is understood that the state has already released a series of signals regarding the centralized procurement of proprietary Chinese medicines
.
For example, in July 2020, the relevant departments of the National Medical Insurance Administration held a symposium on the centralized procurement of biological products and proprietary Chinese medicines to study and improve the procurement policies in related fields and release the signal of centralized procurement or centralized procurement of proprietary Chinese medicines; in September of the same year, the National Medical Insurance A reply from the bureau stated that it will further study and explore the centralized procurement of unreviewed drugs and drugs for which there is no consistent evaluation standard, such as biological products and proprietary Chinese medicines.
.
.
In addition, there are many more.
In recent years, the local government has also carried out a centralized procurement pilot for some varieties of Chinese patent medicines with large demand and high amount, and achieved certain results
.
For example, by the end of 2021, Hubei will lead the formation of an inter-provincial alliance of 19 provinces to carry out the centralized procurement of Chinese patent medicines
.
Recently, Hubei led the 19-province alliance to open bids for the centralized procurement of proprietary Chinese medicines.
The results of this centralized procurement show that a total of 97 companies and 111 products were selected.
The average price of the selected products dropped by 42.
27%, and there were also products that fell by more than 82%
.
The analysis believes that with the development of local pilots for the centralized procurement of Chinese patent medicines in various places and the advancement of various medical reform policies, it has become a general trend that the pace of centralized procurement of Chinese patent medicines will continue to accelerate.
, the national procurement of Chinese patent medicine is just around the corner
.
However, it should be noted that with the arrival of Chinese patent medicines, the industry generally believes that relevant pharmaceutical companies will face the test of price reduction
.
In fact, in the past, the centralized procurement of medicines often led to a large drop in product prices
.
In addition, under the circumstance that medicines face price cuts, the analysis believes that Chinese patent medicine companies will also face risks such as large price fluctuations of raw medicinal materials and difficulty in cost control
.
In this context, how to control costs and ensure quality will become a major difficulty
.
In this regard, some people in the industry suggested that pharmaceutical companies should first be prepared to actively meet regulatory requirements, such as building a Chinese herbal medicine planting base that complies with GAP specifications; at the same time, they should increase investment in research and development, improve quality standards, and speed up the standardization system of traditional Chinese medicine.
Build, form group standards, local standards, industry standards, national standards, international standards, and a multi-level, multi-dimensional, whole-process quality control system covering medicinal materials, intermediates, and finished products
.
In addition, we must also attach importance to and strengthen the modernization research of related pharmaceutical equipment, and design and develop equipment that can better ensure the quality of medicines and can save energy and increase efficiency according to the pharmaceutical needs of Chinese patent medicines
.
The analysis believes that under the background of the continuous promotion of centralized procurement of proprietary Chinese medicines and the approach of national procurement, enterprises will have higher and higher requirements for cost control and quality, and will also require more advanced technology and equipment support
.
Affected by this, relevant pharmaceutical equipment companies will usher in more opportunities
.
But at the same time, if pharmaceutical equipment companies want to seize the opportunity, they must continue to meet the needs of pharmaceutical companies by accelerating innovation and continuously upgrading and upgrading, so as to better ensure quality and control costs for them
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.